JPWO2016081947A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2016081947A5 JPWO2016081947A5 JP2017527368A JP2017527368A JPWO2016081947A5 JP WO2016081947 A5 JPWO2016081947 A5 JP WO2016081947A5 JP 2017527368 A JP2017527368 A JP 2017527368A JP 2017527368 A JP2017527368 A JP 2017527368A JP WO2016081947 A5 JPWO2016081947 A5 JP WO2016081947A5
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- cutpoint
- mutations
- synonymous mutations
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 3
- 108010026276 pembrolizumab Proteins 0.000 claims description 3
- 230000000051 modifying Effects 0.000 claims 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 229920000453 Consensus sequence Polymers 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003505 mutagenic Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Description
抗PD-1療法などの免疫療法の奏効に関する分子決定因子を理解することは、腫瘍学の重要な課題の1つである。最良奏効の1つは現在までに、主に変異誘発物質(それぞれ、紫外線(7)及び肺癌における煙草の煙中の発癌物質(8))への慢性的な曝露により引き起こされる癌であるメラノーマ及びNSCLCの両方に見られている。しかし、腫瘍型の中で、変異バーデンに、10s~1000sの範囲の大きな変動がある(9-11)。喫煙未経験の腫瘍が一般に、喫煙者の腫瘍と比較して、極めて少ない体細胞変異しか有さないが、この範囲は、NSCLCの患者において特に広い(12)。本発明者らは、NSCLCの変異の全体像は、いかに患者に抗PD-1療法が奏効するかに影響を与えることがあると仮定する。NSCLCのゲノムの特徴が抗PD-1療法の効果にどのように影響するかを確かめるために、我々はヒト化IgG4-κアイソタイプ抗PD-1抗体であるペムブロリズマブで処置された患者の2つの独立したコホート(それぞれ、n=16及びn=18;合計n=34)からのNSCLCのエクソーム及びそれらの一致した正常DNAを配列決定した(図15)。
発見コホートでは、非同義変異バーデンとDCBとの間に高い一致がみられ、受信者操作特性曲線下面積(AUC)は87%であった(図1E)。最大の感度と最もよい特異度を組み合わせたカットポイントである178以上の非同義変異バーデンの患者は、DCBに対する尤度比が3.0であり;このカットポイントを使用したDCBの感度及び特異度は、それぞれ100%(95% CI 59~100)及び67%(29~93)であった。このカットポイントを検証コホート内の患者に適用すると、178以上の変異を含む腫瘍を有する患者における持続的効果の比率は、178未満のもの14%と比較して、75%であった。これは、86%の感度及び75%の特異度に対応した。
数は少ないが重要な例外もあった。178以上の非同義変異があった18個の腫瘍のうちの5つがNDBを呈し、非常に少ないバーデン(56の非同義変異)の1つの腫瘍がペンブロリズマブに対して部分奏効を呈した。しかし、この奏効は、一過性であり、わずか8ヶ月しか持続しなかった。両コホートにわたって、腫瘍変異バーデンが178未満で客観的奏効が確認されたのは、この患者のみであった。特に、より高い非同義変異バーデンが、ORR、DCB、及びPFSを予測していた(図1F、1G)が、この相関は、全エキソン変異バーデンを検査した時にあまり明らかでなかった(図16)。
Claims (5)
- 免疫チェックポイント調節因子を用いる肺癌の処置のために、当該処置の候補となるヒト対象を同定するための方法であって、前記方法は、
ヒト対象由来の肺癌サンプルにおける非同義変異を検出する工程と、
非同義変異の検出されたレベルをカットポイントと比較する工程であって、該カットポイントが、178の非同義変異である、工程と、
非同義変異のレベルがカットポイントと同じまたはそれより上であることを前記比較が示す場合に、免疫チェックポイント調節因子を用いる処置の候補として前記対象を同定する工程と、
を含み、
前記免疫チェックポイント調節因子が抗PD-1抗体ペンブロリズマブであり、かつ、
前記肺癌が、非小細胞肺癌(NSCLC)である、
方法。 - 前記検出する工程が、前記癌サンプル由来の1つ以上のエクソームを配列決定することを含む、請求項1に記載の方法。
- 前記変異の1つ以上がT細胞により認識されるネオエピトープに存在する、請求項1に記載の方法。
- 前記ネオエピトープが、感染性因子とコンセンサス配列を共有する、請求項3に記載の方法。
- 前記肺癌が、肺癌腫であるかまたはこれを含む、請求項1に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022129458A JP2023055625A (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083088P | 2014-11-21 | 2014-11-21 | |
US62/083,088 | 2014-11-21 | ||
US201562132381P | 2015-03-12 | 2015-03-12 | |
US62/132,381 | 2015-03-12 | ||
PCT/US2015/062208 WO2016081947A2 (en) | 2014-11-21 | 2015-11-23 | Determinants of cancer response to immunotherapy by pd-1 blockade |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020135853A Division JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Pd−1遮断による免疫療法の癌奏効の決定因子 |
JP2022129458A Division JP2023055625A (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2018502828A JP2018502828A (ja) | 2018-02-01 |
JP2018502828A5 JP2018502828A5 (ja) | 2019-01-10 |
JPWO2016081947A5 true JPWO2016081947A5 (ja) | 2022-09-01 |
JP7173733B2 JP7173733B2 (ja) | 2022-11-16 |
Family
ID=56014697
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017527368A Active JP7173733B2 (ja) | 2014-11-21 | 2015-11-23 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
JP2020135853A Withdrawn JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Pd−1遮断による免疫療法の癌奏効の決定因子 |
JP2022129458A Pending JP2023055625A (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020135853A Withdrawn JP2020196732A (ja) | 2014-11-21 | 2020-08-11 | Pd−1遮断による免疫療法の癌奏効の決定因子 |
JP2022129458A Pending JP2023055625A (ja) | 2014-11-21 | 2022-08-16 | Pd-1遮断による免疫療法の癌奏効の決定因子 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20180291074A1 (ja) |
EP (1) | EP3220950A4 (ja) |
JP (3) | JP7173733B2 (ja) |
CN (2) | CN114672559A (ja) |
AU (2) | AU2015349644B2 (ja) |
CA (1) | CA2968059A1 (ja) |
HK (1) | HK1244440A1 (ja) |
MA (1) | MA40737A (ja) |
WO (1) | WO2016081947A2 (ja) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
CN105026428B (zh) | 2013-12-12 | 2018-01-16 | 上海恒瑞医药有限公司 | PD‑l抗体、其抗原结合片段及其医药用途 |
BR112017008914A2 (pt) | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
AU2017225854B2 (en) * | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
WO2017151517A1 (en) | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
EP3422945B1 (en) * | 2016-03-01 | 2020-12-09 | North Carolina State University | Enhanced cancer immunotherapy by microneedle patch-assisted delivery |
PT3424518T (pt) * | 2016-03-02 | 2021-09-22 | Toray Industries | Indutor de imunidade |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
JP6910653B2 (ja) * | 2016-07-01 | 2021-07-28 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
AU2017315468B2 (en) * | 2016-08-25 | 2020-02-13 | Nantomics, Llc | Immunotherapy markers and uses therefor |
KR20190072528A (ko) * | 2016-10-06 | 2019-06-25 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
JP7295015B2 (ja) * | 2016-10-07 | 2023-06-20 | オムニセック インコーポレイテッド | 個別化治療を決定するための方法 |
US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
ES2971298T3 (es) * | 2017-01-18 | 2024-06-04 | Icahn School Med Mount Sinai | Neoantígenos y usos de los mismos para el tratamiento del cáncer |
CN110430894A (zh) | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
US20200049714A1 (en) * | 2017-02-06 | 2020-02-13 | Novartis Ag | Method of predicting response to immunotherapy |
EP3494235A1 (en) * | 2017-02-17 | 2019-06-12 | Stichting VUmc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
SG11201908530QA (en) * | 2017-03-20 | 2019-10-30 | Genocea Biosciences Inc | Treatment methods |
SG11201908396PA (en) * | 2017-03-31 | 2019-10-30 | Bristol Myers Squibb Co | Methods of treating tumor |
GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
TWI823859B (zh) * | 2017-07-21 | 2023-12-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
WO2019023624A1 (en) * | 2017-07-28 | 2019-01-31 | Bristol-Myers Squibb Company | PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS |
EP3681535A1 (en) * | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
WO2019055860A1 (en) * | 2017-09-15 | 2019-03-21 | The Texas A&M University System | METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER |
BR112020005602A2 (pt) | 2017-09-25 | 2020-10-13 | Memorial Sloan Kettering Cancer Center | carga de mutação de tumor |
CA3076918A1 (en) * | 2017-10-02 | 2019-04-11 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
SG11202002711WA (en) | 2017-10-12 | 2020-04-29 | Nantomics Llc | Cancer score for assessment and response prediction from biological fluids |
EP3694884A1 (en) | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
CN111566225A (zh) | 2017-11-03 | 2020-08-21 | 夸登特健康公司 | 归一化肿瘤突变负荷 |
US20200370124A1 (en) * | 2017-11-17 | 2020-11-26 | Gmdx Co Pty Ltd. | Systems and methods for predicting the efficacy of cancer therapy |
CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
JP7299169B2 (ja) * | 2017-12-01 | 2023-06-27 | イルミナ インコーポレイテッド | 体細胞突然変異のクローン性を決定するための方法及びシステム |
WO2019211418A1 (en) | 2018-05-03 | 2019-11-07 | F. Hoffmann-La Roche Ag | Surrogate marker and method for tumor mutation burden measurement |
US20210246208A1 (en) * | 2018-05-04 | 2021-08-12 | Merck Patent Gmbh | Combined inhibition of pd-1/pd-l1, tgfb and dna-pk for the treatment of cancer |
CN112752854A (zh) | 2018-07-23 | 2021-05-04 | 夸登特健康公司 | 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统 |
US20210292851A1 (en) | 2018-07-27 | 2021-09-23 | Roche Sequencing Solutions, Inc. | Method of monitoring effectiveness of immunotherapy of cancer patients |
US11673927B2 (en) | 2018-08-29 | 2023-06-13 | Tokyo Metropolitan Institute Of Medical Science | Antitumor agent targeting HGF-regulated tyrosine kinase substrate (HGS) |
AU2019328344A1 (en) | 2018-08-31 | 2021-04-08 | Guardant Health, Inc. | Microsatellite instability detection in cell-free DNA |
US20200157642A1 (en) * | 2018-11-15 | 2020-05-21 | Personal Genome Diagnostics, Inc. | Method of improving prediction of response for cancer patients treated with immunotherapy |
JP2022514218A (ja) * | 2018-12-12 | 2022-02-10 | メディミューン,エルエルシー | 血液に基づく腫瘍遺伝子変異量が、非小細胞肺がんの全生存期間の予測に役立つ |
EP3982954A4 (en) * | 2019-06-14 | 2024-01-03 | Univ Columbia | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA |
GB202003669D0 (en) * | 2020-03-13 | 2020-04-29 | Univ Oxford Innovation Ltd | Method for identifying neo-antigens |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
CN112309502A (zh) * | 2020-10-14 | 2021-02-02 | 深圳市新合生物医疗科技有限公司 | 一种计算肿瘤新抗原负荷的方法及系统 |
CA3200667A1 (en) * | 2020-11-06 | 2022-05-12 | The General Hospital Corporation | Methods for characterizing biological samples |
WO2022235482A1 (en) * | 2021-05-03 | 2022-11-10 | Rutgers, The State University Of New Jersey | Immunotherapy for inflammatory bowel disease and/or cancer |
CN113030475B (zh) * | 2021-05-25 | 2021-08-10 | 泛肽生物科技(浙江)有限公司 | 一种基于细胞线粒体质量评估的t细胞pd-1检测方法 |
CN113355424B (zh) * | 2021-07-14 | 2022-03-25 | 江苏先声医学诊断有限公司 | Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033497A1 (en) | 2002-08-13 | 2004-02-19 | Alarcon-Riquelme Marta E. | Polymorphisms of PD-1 |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
EP2499486A4 (en) * | 2009-11-13 | 2013-11-27 | Infinity Pharmaceuticals Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER |
GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
MX339621B (es) * | 2010-04-13 | 2016-06-02 | Celldex Therapeutics Inc * | Anticuerpos que se unen a cd27 humano y uso de los mismos. |
ES2788863T3 (es) * | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores |
DK2844282T3 (da) | 2012-05-04 | 2019-07-15 | Pfizer | Prostata-associerede antigener og vaccine-baserede immunterapiregimener |
DK2901341T3 (da) * | 2012-09-28 | 2019-07-15 | Univ Connecticut | Identifikation af tumorbeskyttelsesepitoper til behandling af cancere |
BR112016015399A2 (pt) * | 2014-01-02 | 2017-10-24 | Memorial Sloan Kettering Cancer Center | método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico |
CN113694193A (zh) * | 2014-11-13 | 2021-11-26 | 约翰·霍普金斯大学 | 检查点阻断和微卫星不稳定性 |
MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
BR112020005602A2 (pt) * | 2017-09-25 | 2020-10-13 | Memorial Sloan Kettering Cancer Center | carga de mutação de tumor |
-
2015
- 2015-11-22 MA MA040737A patent/MA40737A/fr unknown
- 2015-11-23 WO PCT/US2015/062208 patent/WO2016081947A2/en active Application Filing
- 2015-11-23 CA CA2968059A patent/CA2968059A1/en active Pending
- 2015-11-23 AU AU2015349644A patent/AU2015349644B2/en active Active
- 2015-11-23 CN CN202210026426.9A patent/CN114672559A/zh active Pending
- 2015-11-23 CN CN201580073049.2A patent/CN107206064B/zh active Active
- 2015-11-23 EP EP15861224.2A patent/EP3220950A4/en not_active Ceased
- 2015-11-23 JP JP2017527368A patent/JP7173733B2/ja active Active
- 2015-11-23 US US15/528,385 patent/US20180291074A1/en not_active Abandoned
-
2018
- 2018-03-21 HK HK18103939.8A patent/HK1244440A1/zh unknown
-
2019
- 2019-02-22 US US16/283,555 patent/US10993998B2/en active Active
-
2020
- 2020-08-11 JP JP2020135853A patent/JP2020196732A/ja not_active Withdrawn
-
2021
- 2021-03-15 US US17/202,173 patent/US20210308241A1/en active Pending
- 2021-08-09 AU AU2021215099A patent/AU2021215099A1/en active Pending
-
2022
- 2022-08-16 JP JP2022129458A patent/JP2023055625A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2016081947A5 (ja) | ||
Succony et al. | Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies | |
Barton et al. | Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma | |
Zaanan et al. | Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy: a multicenter AGEO study | |
CN109416925A (zh) | 检查点失效和使检查点失效的方法 | |
Yu et al. | Pulmonary metastasectomy in colorectal cancer: a population-based retrospective cohort study using the Korean National Health Insurance Database | |
Kosari et al. | Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors | |
Fornaro et al. | Validated nomogram predicting 6-month survival in pancreatic cancer patients receiving first-line 5-fluorouracil, oxaliplatin, and irinotecan | |
Gao et al. | A novel prognostic model for identifying the risk of hepatocellular carcinoma based on angiogenesis factors | |
Bozkaya et al. | Clinical predictive factors associated with pathologic complete response in locally advanced rectal cancer | |
Yuan et al. | Hepatic tumor stiffness measured by shear wave elastography is prognostic for HCC progression following treatment with anti-PD-1 antibodies plus lenvatinib: A retrospective analysis of two independent cohorts | |
Jimenez et al. | A prospective correlation of tissue histopathology with nucleic acid yield in metastatic castration-resistant prostate cancer biopsy specimens | |
Nawaz et al. | Association of the rs10757274 SNP with coronary artery disease in a small group of a Pakistani population | |
Liu et al. | Identification of SLITRK6 as a Novel Biomarker in hepatocellular carcinoma by comprehensive bioinformatic analysis | |
Pan et al. | Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial | |
Chen et al. | Molecular profiling identifies distinct subtypes across TP53 mutant tumors | |
Chen et al. | The predictive effect of immune therapy and chemotherapy under T cell-related gene prognostic index for Gastric cancer | |
Zou et al. | Risk signature related to immunotherapy reaction of hepatocellular carcinoma based on the immune-related genes associated with CD8+ T cell infiltration | |
Ma et al. | Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC | |
Ma | Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis | |
Kyzer et al. | Proliferative activity of colonic mucosa at different distances from primary adenocarcinoma as determined by the presence of statin: a nonproliferation-specific nuclear protein | |
Bang et al. | 2256P The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study | |
Wang et al. | Low expression of bestrophin-2 is associated with poor prognosis in colon cancer | |
Myasnyankin et al. | Final results of neoadjuvant photodynamic therapy (PDT) on the indices of T-and B-cellar immune answer in the surgical treatment of patients with gastric cancer | |
Evans | Survival and Biomarker Trends for Non-small Cell Lung Cancer with the Implementation of Cuban Developed Therapies |